Literature DB >> 2540357

[Clinical evaluation of fluconazole in the case of deep mycosis associated with leukemia].

A Maruta1, M Matsuzaki, H Fukawa, F Kodama.   

Abstract

The clinical efficacy of fluconazole at doses of 100-400 mg daily given intravenously in the treatment of 6 cases of deep mycosis complicated with leukemia was evaluated. Types of leukemia as underlying disease were acute lymphatic leukemia in 4 patients (included post bone marrow transplantation in 2 patients), acute myelocytic leukemia in 1 and acute myelomonocytic leukemia (AMMoL) in 1. Causative fungi were Candida in all patients. Diagnoses established were pulmonary or bronchial candidiasis in 3 patients, candiduria in 2 and suspected candidemia accompanied with stomatitis in 1. A patient with candiduria died from AMMoL thus the evaluation of efficacy was made with 5 patients. Overall clinical efficacies were judged to be good in 3 cases of pulmonary or bronchial candidiasis and in 1 case of suspected candidemia accompanied with stomatitis and excellent in 1 case of candiduria with an efficacy rate of 100%. No side effect, either subjective or objective, was reported with any patient. In clinical laboratory tests, elevations of serum transaminase and Al-P were observed in 2 patients and a rise of S-Cr. in 1, but all these abnormalities were judged to be related to the drugs for leukemia treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2540357

Source DB:  PubMed          Journal:  Jpn J Antibiot        ISSN: 0368-2781


  4 in total

1.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 2.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

3.  The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.

Authors:  Satoshi Sobue; Keith Tan; Gary Layton; Violette Leclerc; Angelika Weil
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

Review 4.  Safety of fluconazole in paediatrics: a systematic review.

Authors:  Oluwaseun Egunsola; Abiodun Adefurin; Apostolos Fakis; Evelyne Jacqz-Aigrain; Imti Choonara; Helen Sammons
Journal:  Eur J Clin Pharmacol       Date:  2013-01-17       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.